Patent ID: 6939855
Filing Date: 2005-09-06
Classification: A61K,C07K

Abstract:
1. A method of treating an inflammatory disorder in a mammalian patient, which disorder involves binding of alpha-9 integrin to an alpha-9 integrin ligand in a mammalian patient, and which disorder is selected from the group consisting of asthma, rheumatoid arthritis, multiple sclerosis, viral meningitis, encephalitis, and ulcerative colitis said method comprising administering to a mammalian subject in need thereof an effective dosage of an alpha-9 integrin antagonist compound which compound is represented by the formula: wherein: R R R R Ar is aryl, heteroaryl, substituted aryl or substituted heteroaryl, X is an integer of from 1 to 4; Q is —C(X)NR pharmaceutically acceptable salts thereof, wherein said compound has a K